Alteration of Sex and Non-Sex Hormones and Distribution Features of Blood ABO System Groups among the Women with Uterine Body Tumors

Abstract

Objectives: The aim of the investigation was to study the hormonal status (sex hormones: estradiol (E 2), progesterone (P), testosterone (T); non-sex gonadotropic hormones-luteinizing hormone (LH) and follicle-stimulating hormone (FSH)) of women with benign and malignant tumors of uterine body in the reproductive, menopause and postmenopause periods. Also the distribution features of the blood ABO system phenotype groups and their link to the development of uterine body tumors have been studied. Methods: The determination of hormones was made by the enzyme analysis method (ELAIZA), provided by the proper ELAIZA kits. For the study of blood ABO system antigens, internationally recognized immunoserology methods were used. Results: Investigations revealed the increased level of E 2 and T on the background of the reduced P in the blood of the women with uterine tumors in the reproductive, menopause and post-menopause period. As for gonadotropic hormones, the decreased levels of LH and FSH have also been detected. From the ABO system phenotype groups A(II) group had the highest frequency between the women with malignant uterine tumor in the reproductive age. O (I) phenotype group was the most frequent in case of menopause and post-menopause women with uterine malignant tumors. Conclusions: Hormonal imbalance creates good conditions for the proliferation of uterine tissues and hence causes the development of benign and malignant uterine tumors. The imbalance of the sex steroid and gonadotropic hormones in the blood of post-menopause women indicates on the genotoxic * Corresponding author. mechanism of cancer development on the background of age-related changes. A(II) group had the highest frequency between the reproductive age women with uterine malignant tumor, while O (I) group was the most frequent in case of menopause and post-menopause patients.

Prognostic Impact of ABO Blood Group on Type I Endometrial Cancer Patients- Results from Our Own and Other Studies

“…On contrary, the O blood group was associated with high risk of EC in menopause and post-menopause women 21 and in another study no statistically significant correlations were obtained for EC and ABO 22 .…”

“…Previous studies reported that the A blood group was associated with high risk of EC 29 particularly in reproductive age 21 .…”

“…In a study, A blood group had the highest frequency between the women with EC in the reproductive age. O phenotype group was the most frequent in case of menopause and post-menopause women with EC 21 . On contrary in another study no statistically significant correlations were obtained for EC and ABO blood groups 22 .…”

Autoimmune thyroiditis in different age groups and subjects of reproductive age in Adzhariya population

“…Соответственно, повышается и/или снижается риск развития различных заболеваний щитовидной железы, в том числе аутоиммунных; кроме того, функция щитовидной железы может участвовать в патогенезе других климактерических осложнений [33]. Они также изменяют синтез половых стероидных гормонов [34], что значительно повышает риск развития заболеваний женских репродуктивных органов, в том числе опухолей [35,36].…”

Association of group erythrocyte antigens and B-cell non-Hodgkin lymphoma

“…Встановлено підвищений ризик розвитку раку молочної залози, товстої кишки, підшлунковаї залози, стравоходу, сечового міхура, яєчників, легень, шкіри, щитовидної залози, печінки з груповими еритроцитарними антигенами. Також доведено вплив антигенів груп крові АВ0, Rhesus, Kell на ступінь диференціювання злоякісних клітин, а також чутливість пухлини до терапії, загальну виживаність (Yuzhalin and Kutikhin, 2012;Pelzer et al, 2013;Urun et al, 2013;Abobaker et al, 2014;Aly et al, 2014;Cao et al, 2014;Kumar et al, 2014;Mansour et al, 2014;Nakashidze et al, 2014;Upma and Fotra, 2016). Іноді дані про розподіл антигенів еритроцитів у хворих із різною патологією неоднозначні, але наявність тих або інших еритроцитарних специфічностей у людини може бути фактором ризику виникнення певного захворювання, у тому числі й онкогематологічного (Cihan, 2014;Mansour et al, 2014;Engel et al, 2015;Flegr, 2016).…”